Inhibition of Tachykinin Nk1receptor Using Aprepitant Induces Apoptotic Cell Death and G1 Arrest Through Akt/P53 Axis in Pre-B Acute Lymphoblastic Leukemia Cells Publisher Pubmed



Bayati S^{1, 2} ; Bashash D³ ; Ahmadian S¹ ; Safaroghliazar A³ ; Alimoghaddam K² ; Ghavamzadeh A² ; Ghaffari SH² Show Affiliations
Source: European Journal of Pharmacology Published:2016

Abstract

Increasing number of genetic and cancer biology studies indicated a prominent role for tachykinin NK1receptor (NK1R) in cancer cell growth and survival. Considering the fact that neoplastic lymphoid precursors in acute lymphoblastic leukemia (ALL) carry a three- to four-fold NK1R expression as compared to normal lymphocytes, using NK1R antagonist seems to be noteworthy in the treatment of ALL patients. In this study, we found that inhibition of NK1R with aprepitant, a selective high-affinity antagonist of the human NK1R, exerts cytotoxic and anti-proliferative effects against pre-B ALL-derived Nalm-6 cells either as single drug or in combination with doxorubicin. Our data showed that treatment of the cells with the inhibitor resulted in apoptotic cell death, at least partly, through abrogation of PI3K/Akt pathway, as revealed by the reduction of phospho/total Akt ratio. In agreement with the inhibitory effect on Akt, we also found that aprepitant increased the expression level of p21 and p27, which in turn leads to the induction of G1 cell cycle arrest. Overall, this study recommends mechanistic pathways by which inhibition of NK1R can augment apoptotic cell death through a plausible p53-dependent pathway rather than NF-κB-depended mechanism in pre-B ALL cells; however, further studies are needed to better characterize the application of NK1R inhibition in clinical cancer treatment. © 2016 Elsevier B.V.